NCT05704725View on ClinicalTrials.gov

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

PHASE3CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

February 17, 2023

Study Completion Date

March 24, 2023

Conditions
Chorioretinal Vascular Disease
Interventions
DRUG

ABP 938

IVT injection

DRUG

Aflibercept

IVT injection

Trial Locations (4)

77384

Retina Consultants of Texas - The Woodlands Retina Center, The Woodlands

77401

Retina Consultants of Texas - Bellaire Retina Center, Bellaire

78705

Retina Consultants of Texas - Austin Retina, Austin

78240-1657

Retinal Consultants of Texas - San Antonio Retina Center, San Antonio

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05704725 - A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) | Biotech Hunter | Biotech Hunter